The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase II trial of preoperative chemoradiotherapy and pembrolizumab for locally advanced esophageal squamous cell carcinoma (ESCC).
 
Min Hee Hong
Honoraria - Presentation
Consulting or Advisory Role - AstraZeneca; Roche
Speakers' Bureau - AstraZeneca; Roche
Research Funding - AstraZeneca
 
HyeRyun Kim
No Relationships to Disclose
 
Seong Yong Park
No Relationships to Disclose
 
Dae Joon Kim
No Relationships to Disclose
 
Chang Geol Lee
No Relationships to Disclose
 
Jaeho Cho
No Relationships to Disclose
 
Jong Hoon Kim
No Relationships to Disclose
 
Hyeong Ryul Kim
No Relationships to Disclose
 
Yong-Hee Kim
No Relationships to Disclose
 
Sook Ryun Park
No Relationships to Disclose
 
Byoung Chul Cho
Stock and Other Ownership Interests - Theravance
Honoraria - AstraZeneca; Bayer; Champions Oncology; Dizal Pharma; Dong-A ST; Janssen; Mogam Biotechnology Research Institue; MSD; Novartis; Ono Pharmaceutical; Yuhan
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Janssen; Lilly; MSD; Novartis; Ono Pharmaceutical; Pfizer; Roche; Takeda; Yuhan
Speakers' Bureau - Novartis
Research Funding - AstraZeneca; Bayer; Champions Oncology; Dizal Pharma; Dong-A ST; Janssen; Mogam Biotechnology Research Institue; MSD; Novartis; Ono Pharmaceutical; Yuhan
Patents, Royalties, Other Intellectual Property - Champions Oncology